10.48
price down icon0.10%   -0.010
after-market After Hours: 10.67 0.19 +1.81%
loading
Eyepoint Pharmaceuticals Inc stock is traded at $10.48, with a volume of 406.34K. It is down -0.10% in the last 24 hours and down -0.57% over the past month. EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$10.49
Open:
$10.45
24h Volume:
406.34K
Relative Volume:
0.52
Market Cap:
$721.14M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-5.7582
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+0.58%
1M Performance:
-0.57%
6M Performance:
+22.86%
1Y Performance:
+10.78%
1-Day Range:
Value
$10.12
$10.52
1-Week Range:
Value
$10.12
$11.08
52-Week Range:
Value
$3.91
$13.98

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name
Name
Eyepoint Pharmaceuticals Inc
Name
Phone
617-926-5000
Name
Address
480 PLEASANT STREET, WATERTOWN, MA
Name
Employee
144
Name
Twitter
@eyepointpharma
Name
Next Earnings Date
2025-03-05
Name
Latest SEC Filings
Name
EYPT's Discussions on Twitter

Compare EYPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
EYPT
Eyepoint Pharmaceuticals Inc
10.48 721.84M 46.02M -70.80M -1.61M -1.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-25 Initiated RBC Capital Mkts Outperform
Jan-07-25 Initiated Citigroup Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-28-24 Initiated Jefferies Buy
Jan-22-24 Initiated JP Morgan Overweight
Nov-02-23 Initiated Mizuho Buy
Apr-21-23 Initiated Robert W. Baird Outperform
Jul-07-22 Initiated Chardan Capital Markets Buy
Mar-01-21 Initiated Cowen Outperform
Jan-28-21 Initiated Cantor Fitzgerald Overweight
Apr-06-20 Downgrade B. Riley FBR Buy → Neutral
Nov-04-19 Resumed Laidlaw Buy
Sep-12-19 Initiated Guggenheim Buy
View All

Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News

pulisher
04:24 AM

Is it the right time to buy EyePoint Pharmaceuticals Inc. stockMaximize gains with data-driven stock picks - jammulinksnews.com

04:24 AM
pulisher
03:54 AM

How many analysts rate EyePoint Pharmaceuticals Inc. as a “Buy”Capitalize on proven trading setups - jammulinksnews.com

03:54 AM
pulisher
03:31 AM

Is EyePoint Pharmaceuticals Inc. a growth stock or a value stockFree Consultation - jammulinksnews.com

03:31 AM
pulisher
02:40 AM

Does EyePoint Pharmaceuticals Inc. stock perform well during market downturnsBuild your wealth with consistent stock growth - jammulinksnews.com

02:40 AM
pulisher
Jul 26, 2025

Why EyePoint Pharmaceuticals Inc. stock attracts strong analyst attentionFree Access to Community - Metal.it

Jul 26, 2025
pulisher
Jul 26, 2025

What makes EyePoint Pharmaceuticals Inc. stock price move sharplyFree Expert-Led Investment Training - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

How high can EyePoint Pharmaceuticals Inc. stock price go in 2025Market-leading growth rates - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying EyePoint Pharmaceuticals Inc. stock nowFree Stock Market Trend Analysis - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is EyePoint Pharmaceuticals Inc. a good long term investmentStrong return on assets - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about EyePoint Pharmaceuticals Inc. stockExceptional profit margins - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

EyePoint Pharmaceuticals Inc. Stock Analysis and ForecastExceptional portfolio growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 22, 2025

What drives EyePoint Pharmaceuticals Inc. stock priceGame-changing returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 16, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jul 16, 2025
pulisher
Jul 16, 2025

EyePoint Pharmaceuticals Awards 63,900 Shares in Employee Stock Options Under NASDAQ Rule - Stock Titan

Jul 16, 2025
pulisher
Jul 15, 2025

EyePoint Pharmaceuticals Acquisition by Federated Hermes Highlights Interest in Healthcare Sector - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

Pleasing Signs As A Number Of Insiders Buy EyePoint Pharmaceuticals Stock - simplywall.st

Jul 14, 2025
pulisher
Jul 09, 2025

EyePoint Pharmaceuticals (EYPT) Soars 10.15% on Clinical Trial Progress - AInvest

Jul 09, 2025
pulisher
Jul 05, 2025

Trend Tracker for (EYPT) - news.stocktradersdaily.com

Jul 05, 2025
pulisher
Jun 30, 2025

EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) dropped from Russell 3000E Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 20, 2025

EyePoint Pharmaceuticals Approves Share Increase at Annual Meeting - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - MarketScreener

Jun 17, 2025

Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):